Literature DB >> 8583244

TGF alpha expression in meningioma--tumor progression and therapeutic response.

R M Linggood1, D W Hsu, J T Efird, F S Pardo.   

Abstract

Little is known of the molecular genetic mechanisms contributing to meningioma tumor progression. We evaluated a total of 26 clinical cases of meningioma: twenty three patients with meningioma treated at our institution between 1978 and 1990 and three asymptomatic cases found initially at autopsy. In addition, histologically normal meninges obtained at post-mortem examination from 5 cases were evaluated. There were 13 men and 10 women in the patient group with a median age of 48.7 years, treated by surgery and/or irradiation. Median follow-up was 46 months (range 16-152 months). Archival cases and age-matched normal meningeal tissue obtained at autopsy during the same time period were obtained for study. Patients with TGF alpha scores greater than 3.0 were more likely to fail treatment and had lower overall survival times than those with immunostaining scores of 1 or 2. Three autopsy cases where meningioma had been silent clinically had overall staining scores of 0.75, while 10 samples of normal meninges harvested from 5 cases at autopsy had staining scores of 0. Two patients each underwent 3 surgeries for recurrent tumor, serial specimens showed increased TGF alpha expression over time, though all material from these procedures was consistent with the diagnosis of histologically benign meningioma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583244     DOI: 10.1007/bf01054768

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Neurology of sex steroids and oral contraceptives.

Authors:  H M Schipper
Journal:  Neurol Clin       Date:  1986-11       Impact factor: 3.806

2.  Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.

Authors:  M Shibuya; T Hoshino; S Ito; M R Wacker; M D Prados; R L Davis; C B Wilson
Journal:  Neurosurgery       Date:  1992-04       Impact factor: 4.654

3.  Histopathologic features predicting recurrence of meningiomas following subtotal resection.

Authors:  S M de la Monte; J Flickinger; R M Linggood
Journal:  Am J Surg Pathol       Date:  1986-12       Impact factor: 6.394

4.  Role of radiation therapy in the management of meningioma.

Authors:  R J Carella; J Ransohoff; J Newall
Journal:  Neurosurgery       Date:  1982-03       Impact factor: 4.654

5.  DNA-fluorescence-cytometry and prognosis (grading) of meningiomas--a study of 104 surgically removed tumors.

Authors:  F W Spaar; A Ahyai; M Blech
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

6.  Radiation therapy in the treatment of partially resected meningiomas.

Authors:  N M Barbaro; P H Gutin; C B Wilson; G E Sheline; E B Boldrey; W M Wara
Journal:  Neurosurgery       Date:  1987-04       Impact factor: 4.654

7.  The role of radiation therapy in the management of intracranial meningiomas.

Authors:  M J Solan; S Kramer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-04       Impact factor: 7.038

Review 8.  Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990.

Authors:  B J Goldsmith; W M Wara; C B Wilson; D A Larson
Journal:  J Neurosurg       Date:  1994-02       Impact factor: 5.115

9.  Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.

Authors:  J W Koper; E C Zwarthoff; A Hagemeijer; R Braakman; C J Avezaat; M Bergström; S W Lamberts
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  Radiation therapy in the treatment of meningioma: the Joint Center for Radiation Therapy experience 1970 to 1982.

Authors:  A R Forbes; I D Goldberg
Journal:  J Clin Oncol       Date:  1984-10       Impact factor: 44.544

View more
  6 in total

Review 1.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

2.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Authors:  Andrew D Norden; Jeffrey J Raizer; Lauren E Abrey; Kathleen R Lamborn; Andrew B Lassman; Susan M Chang; W K Alfred Yung; Mark R Gilbert; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Timothy F Cloughesy; H Ian Robins; Kenneth Aldape; Janet Dancey; Michael D Prados; Frank Lieberman; Patrick Y Wen
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

3.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

4.  Correlation of granulin expression in intracranial meningiomas to clinical parameters.

Authors:  Choong Hyun Kim; Jin Hwan Cheong; Jae Min Kim
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

Review 5.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

6.  EGFR soluble isoforms and their transcripts are expressed in meningiomas.

Authors:  Angélique Guillaudeau; Karine Durand; Barbara Bessette; Alain Chaunavel; Isabelle Pommepuy; Fabrice Projetti; Sandrine Robert; François Caire; Hélène Rabinovitch-Chable; François Labrousse
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.